Centrient Pharmaceuticals India Private Limited, a active private limited company, was established on 19 January 1993 in Toansa, Punjab, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231PB1993PTC023090. Registered under ROC Roc Chandigarh. it is unlisted. It has an authorized capital of ₹170.00 Cr and a paid-up capital of ₹160.30 Cr.
Formerly known as Dsm Sinochem Pharmaceuticals India Limited, Dsm Anti Infectives India Private Limited. It upholds a compliant status. Employing 613 professional, Its leadership includes Namit Joshi (Whole-Time Director), Vikram Aditya Sehgal (Cfo), Devesh Prakash Srivastava (Whole-Time Director). Past directors included Shalabh Goel, Ramanan Venkat Natarajan, Bhawna Singhal. It holds ₹200.00 Cr open charges and no settled loans. Its latest AGM occurred on 10 September 2025, with the balance sheet filed on 31 March 2025. It is based at Bhai Mohan Singh Nagar, Toansa, Punjab, 144533.
U24231PB1993PTC023090
023090
19 January 1993
₹170.00 Cr
₹160.30 Cr
Roc Chandigarh
Unlisted
Active
Explore comprehensive insights into Centrient Pharmaceuticals India Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Namit Joshi | Whole-Time Director | 29 Jul 2021 | Current |
| Vikram Aditya Sehgal | Cfo | 04 Jun 2021 | Current |
| Devesh Prakash Srivastava | Whole-Time Director | 01 Apr 2023 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 27 Sep 2019 | Past |
| Pramod Abcsdd | Director | 16 Nov 2009 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2016 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2021 | Past |
| Pramod Abcsdd | Cfo(Kmp) | 31 May 2016 | Past |
| Pramod Abcsdd | Additional Director | 14 Sep 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Centrient Pharmaceuticals India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.46% increase. The company also saw a substantial fall in profitability, with a 31.41% decrease in profit. The company's net worth moved up by a moderate rise of 8.75%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Centrient Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,000,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Oct 2018 | Others | ₹200.00 Cr | Open |
Explore comprehensive loan charge details -
Centrient Pharmaceuticals India has a workforce of 613 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Centrient Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Centrient Pharmaceuticals India's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Centrient Pharmaceuticals India Private Limited last Annual general meeting of members was held on 10 Sep 2025 as per latest MCA records. was recorded as a recent event.
Centrient Pharmaceuticals India Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chandigarh. was recorded as a recent event.
The activity A charge with Others of Rs. 200.00 Cr registered on 31 Oct 2018 with Charge ID 100212988 was modified on 21 Jun 2024. was completed.
Devesh Prakash Srivastava was appointed as a Whole-time director was appointed as a Whole-time director on 01 Apr 2023 & has been associated with this company since 2 years 8 months . was recorded as a recent event.
Namit Joshi was appointed as a Whole-time director was appointed as a Whole-time director on 29 Jul 2021 & has been associated with this company since 4 years 4 months . was recorded as a recent event.
Vikram Aditya Sehgal was appointed as a CFO was appointed as a CFO on 04 Jun 2021 & has been associated with this company since 4 years 5 months . was recorded as a recent event.
The CIN of Centrient Pharmaceuticals India Private Limited is U24231PB1993PTC023090.
Centrient Pharmaceuticals India Private Limited is headquartered at Bhai Mohan Singh Nagar, Toansa, Punjab, 144533.
Centrient Pharmaceuticals India Private Limited was incorporated on 19 January 1993.
The current directors of Centrient Pharmaceuticals India Private Limited are
The primary industry of Centrient Pharmaceuticals India Private Limited is Manufacturing.
Centrient Pharmaceuticals India Private Limited is unlisted.
The authorized capital of Centrient Pharmaceuticals India Private Limited is ₹170.00 Cr, and the paid-up capital is ₹160.30 Cr.
The compliance status of Centrient Pharmaceuticals India Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX